Commercial Intelligence
Commercial Intelligence/Targets & Forecast
Targets & Forecast
Forecast performance, target attainment and commercial outlook.
1 – 30 Jun 2026·All Divisions·All Regions·All Categories·Landing view
Orbit Forecast Briefing
Updated 14 min ago
Current forecasting projects a 94.6% national landing. Gauteng North and Cardiaxol account for most of the remaining gap, while Western Cape is expected to exceed plan. Three early interventions could recover approximately R2.8m before month end.
Forecast Landing
94.6%
BelowR32.7m gap to target
Forecast Confidence
78%
Stable vs prior period
Gap to Target
R32.7m
Gap5.4% below plan
Products At Risk
4
of 8 tracked SKUs
Territories At Risk
3
Gauteng N, PE, Limpopo
Recoverable Revenue
R2.8m
ActionableThrough 3 interventions
Current forecast
94.6%
Trajectory with today's plan
Optimistic
97.2%
3 interventions land + demand holds
Conservative
91.8%
Backorders unresolved + Gauteng flat
Required for target
100%
R32.7m additional required
Forecast Landing
Actual · Forecast · Target · Confidence band
Actual
Forecast
Target
Confidence
Intervention Opportunities
Recover forecast gap
Expedite Cardiaxol batch+R1.6m
Supply Planning82% probability
Redistribute Respireze+R0.8m
Distribution90% probability
Extend Gastraven to WC+R1.2m
Commercial74% probability
Gauteng North KAM outreach+R0.6m
Sales68% probability
Forecast Waterfall
Contributors to landing vs 100% target · R millions
Territory Forecast Ranking
Landing % against target
Cape Metro
108%
Cape Winelands
105%
Durban North
97%
Bloemfontein
98%
Gauteng South
91%
PE Metro
87%
Gauteng North
79%
Limpopo
79%
Risks & opportunities
Prioritised for this period
Risks
Cardiaxol forecast miss-R1.6m
Gauteng North below plan-21 pp
Stock constraint affecting forecast-R1.4m
Respireze demand softening-R0.8m
Opportunities
Accelerate high-growth brands+R1.2m
Increase wholesaler replenishment+R0.8m
Recover through key accounts+R0.6m
Extend Gastraven to WC accounts+R0.6m
Cross-page investigation
Follow the commercial thread
Forecast detail by product
Landing %, gap, confidence and recommended action
| Product | Forecast | Target | Gap | Confidence | Recommended action |
|---|---|---|---|---|---|
| Cardiaxol 20mg | 96% | 100% | -4 pp | 74% | Expedite supply |
| Cardiaxol 40mg | 93% | 100% | -7 pp | 71% | Confirm ETA |
| Respireze Inhaler | 82% | 100% | -18 pp | 64% | Redistribute stock |
| Gastraven 20mg | 112% | 100% | +12 pp | 88% | Extend to WC |
| Pulmavent DPI | 78% | 100% | -22 pp | 58% | Escalate supply |
| Neurospen 500 | 86% | 100% | -14 pp | 62% | Review pricing |
| Metaform 850 | 91% | 100% | -9 pp | 70% | Refresh call plan |